Symphogen is a subsidiary of Servier and antibody center of excellence primarily focused on oncology and immune-oncology. We have a highly efficient antibody discovery and research platform supported by comprehensive early development capabilities.

Our antibody platform delivers antibodies with unique functionalities providing best or first in class potential as combination or mono therapy. Our approach and capabilities are well suited for combination therapies at the core of future cancer treatment.